{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:15:32Z","timestamp":1783296932942,"version":"3.54.6"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) affects millions of people globally. Accurate early diagnosis remains a challenge due to the lack of specific biomarkers. This systematic review explores the potential of\n                    <jats:sup>1<\/jats:sup>\n                    H-NMR metabolomics in identifying diagnostic markers and therapeutic targets for PD. A comprehensive analysis was conducted across databases such as Scopus, Web of Science, PubMed, and Embase, focusing on studies that utilized\n                    <jats:sup>1<\/jats:sup>\n                    H-NMR spectroscopy to profile metabolites associated with PD progression. The review identifies key metabolites\u2014glutamate, taurine, myo-inositol, glutamine, and creatine\u2014that play critical roles in the pathophysiology of PD. Glutamate, linked to excitotoxicity and neuronal degeneration, emerges as a prominent target for therapeutic intervention, while taurine is associated with oxidative stress. Myo-inositol, a key regulator of autophagy, underscores the biochemical dysregulation associated with PD, similar to glutamine and glutamate. Creatine\u2019s role in neuronal energy metabolism suggests potential avenues for treatment focused on energy supplementation. The reproducibility of metabolite findings varied, indicating the complexity of PD\u2019s metabolomic landscape. Despite challenges in consistency, these metabolites hold promise as biomarkers for diagnosing PD and tracking disease progression. The review underscores the need for further validation of these markers and their integration with other omics technologies to enhance PD management. By identifying key metabolic pathways, this study opens new directions for personalized medicine, offering potential therapeutic targets to slow disease progression and improve patient outcomes.\n                  <\/jats:p>","DOI":"10.2478\/aite-2025-0011","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:58:57Z","timestamp":1744354737000},"source":"Crossref","is-referenced-by-count":6,"title":["Exploring Diagnostic Markers and Therapeutic Targets in Parkinson\u2019s Disease: A Comprehensive\n                    <sup>1<\/sup>\n                    H-NMR Metabolomic Analysis \u2013 Systematic Review"],"prefix":"10.2478","volume":"73","author":[{"given":"Andrzej","family":"Wasilewski","sequence":"first","affiliation":[{"name":"Student Scientific Association of Medical Chemistry and Immunochemistry , Wroclaw Medical University , Wroclaw , Poland"},{"name":"Faculty of Medicine , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Wasilewska","sequence":"additional","affiliation":[{"name":"Department of Allergology , Medical University of Gdansk , Gdansk , Poland"},{"name":"Center of Rare Disease , Centre University Hospital , Gdansk , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Serrafi","sequence":"additional","affiliation":[{"name":"Department of Immunochemistry and Chemistry , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2026070523570932864_j_aite-2025-0011_ref_001","doi-asserted-by":"crossref","unstructured":"Andersen AD, Binzer M, Stenager E et al. (2017) Cerebrospinal fluid biomarkers for Parkinson\u2019s disease: a systematic review. Acta Neurol Scand 135:34\u201356. https:\/\/doi.org\/10.1111\/ane.12590","DOI":"10.1111\/ane.12590"},{"key":"2026070523570932864_j_aite-2025-0011_ref_002","doi-asserted-by":"crossref","unstructured":"Carvalho C, Correia SC, Cardoso S et al. (2015) The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases. Expert Rev Neurother 15:867\u2013884. https:\/\/doi.org\/10.1586\/14737175.2015.1058160","DOI":"10.1586\/14737175.2015.1058160"},{"key":"2026070523570932864_j_aite-2025-0011_ref_003","doi-asserted-by":"crossref","unstructured":"Caudle WM, Bammler TK, Lin Y et al. (2010) Using \u201comics\u201d to define pathogenesis and biomarkers of Parkinson\u2019s disease. Expert Rev Neurother 10:925\u2013942. https:\/\/doi.org\/10.1586\/ern.10.54","DOI":"10.1586\/ern.10.54"},{"key":"2026070523570932864_j_aite-2025-0011_ref_004","doi-asserted-by":"crossref","unstructured":"Chaturvedi RK, Beal MF (2013) Mitochondria targeted therapeutic approaches in Parkinson\u2019s and Huntington\u2019s diseases. Mol Cell Neurosci 55:101\u2013114. https:\/\/doi.org\/10.1016\/j.mcn.2012.11.011","DOI":"10.1016\/j.mcn.2012.11.011"},{"key":"2026070523570932864_j_aite-2025-0011_ref_005","doi-asserted-by":"crossref","unstructured":"Derkinderen P, Shannon KM, Brundin P (2014) Gut feelings about smoking and coffee in Parkinson\u2019s disease. Mov Disord 29: 976\u2013979. https:\/\/doi.org\/10.1002\/mds.25882","DOI":"10.1002\/mds.25882"},{"key":"2026070523570932864_j_aite-2025-0011_ref_006","doi-asserted-by":"crossref","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3:461\u2013491. https:\/\/doi.org\/10.3233\/JPD-130230","DOI":"10.3233\/JPD-130230"},{"key":"2026070523570932864_j_aite-2025-0011_ref_007","doi-asserted-by":"crossref","unstructured":"Dorsey ER, Sherer T, Okun MS et al. (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8(Suppl. 1):S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","DOI":"10.3233\/JPD-181474"},{"key":"2026070523570932864_j_aite-2025-0011_ref_008","doi-asserted-by":"crossref","unstructured":"Drexler DM, Reily MD, Shipkova PA (2011) Advances in mass spectrometry applied to pharmaceutical metabolomics. Anal Bioanal Chem 399:2645\u20132653. https:\/\/doi.org\/10.1007\/s00216-010-4370-8","DOI":"10.1007\/s00216-010-4370-8"},{"key":"2026070523570932864_j_aite-2025-0011_ref_009","doi-asserted-by":"crossref","unstructured":"Evans AM, DeHaven CD, Barrett T et al. (2009) Integrated, non-targeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656\u20136667. https:\/\/doi.org\/10.1021\/ac901536h","DOI":"10.1021\/ac901536h"},{"key":"2026070523570932864_j_aite-2025-0011_ref_010","doi-asserted-by":"crossref","unstructured":"Gelpi E, Navarro-Otano J, Tolosa E et al. (2014) Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29:1010\u20131018. https:\/\/doi.org\/10.1002\/mds.25776","DOI":"10.1002\/mds.25776"},{"key":"2026070523570932864_j_aite-2025-0011_ref_011","doi-asserted-by":"crossref","unstructured":"Graham SF, Rey NL, Yilmaz A et al. (2018) Biochemical profiling of the brain and blood metabolome in a mouse model of prodromal Parkinson\u2019s disease reveals distinct metabolic profiles. J Proteome Res 17:2460\u20132469. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00224","DOI":"10.1021\/acs.jproteome.8b00224"},{"key":"2026070523570932864_j_aite-2025-0011_ref_012","doi-asserted-by":"crossref","unstructured":"Guo L, Milburn MV, Ryals JA et al. (2015) Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Soc U S A 112:E4901\u2013E4910. https:\/\/doi.org\/10.1073\/pnas.1508425112","DOI":"10.1073\/pnas.1508425112"},{"key":"2026070523570932864_j_aite-2025-0011_ref_013","doi-asserted-by":"crossref","unstructured":"Hall S, Surova Y, \u00d6hrfelt A et al. (2015) CSF biomarkers and clinical progression of Parkinson disease. Neurology 84:57\u201363. https:\/\/ doi.org\/10.1212\/WNL.0000000000001098","DOI":"10.1212\/WNL.0000000000001098"},{"key":"2026070523570932864_j_aite-2025-0011_ref_014","doi-asserted-by":"crossref","unstructured":"Hiller K, Hangebrauk J, J\u00e4ger C et al. (2009) MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC\/ MS based metabolome analysis. Anal Chem 81:3429\u20133439. https:\/\/doi.org\/10.1021\/ac802689c","DOI":"10.1021\/ac802689c"},{"key":"2026070523570932864_j_aite-2025-0011_ref_015","doi-asserted-by":"crossref","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144:151\u2013164. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.011","DOI":"10.1016\/j.jphs.2020.07.011"},{"key":"2026070523570932864_j_aite-2025-0011_ref_016","doi-asserted-by":"crossref","unstructured":"Kozio\u0142 A, Pupek M, Lewandowski \u0141 (2023) Application of metabolomics in diagnostics and differentiation of meningitis: a narrative review with a critical approach to the literature. Biomed Pharmacother 168:115685. https:\/\/doi.org\/10.1016\/j.biopha.2023.115685","DOI":"10.1016\/j.biopha.2023.115685"},{"key":"2026070523570932864_j_aite-2025-0011_ref_017","doi-asserted-by":"crossref","unstructured":"Kumari S, Kumaran SS, Goyal V et al. (2020a) Metabolomic analysis of serum using proton NMR in 6-OHDA experimental PD model and patients with PD. Neurochem Int 134:104670. https:\/\/doi.org\/10.1016\/j.neuint.2020.104670","DOI":"10.1016\/j.neuint.2020.104670"},{"key":"2026070523570932864_j_aite-2025-0011_ref_018","doi-asserted-by":"crossref","unstructured":"Kumari S, Kumaran SS, Goyal V et al. (2020b) Identification of potential urine biomarkers in idiopathic Parkinson\u2019s disease using NMR. Clin Chim Acta 510:442\u2013449. https:\/\/doi.org\/10.1016\/j.cca.2020.08.005","DOI":"10.1016\/j.cca.2020.08.005"},{"key":"2026070523570932864_j_aite-2025-0011_ref_019","doi-asserted-by":"crossref","unstructured":"Lawton KA, Berger A, Mitchell M et al. (2008) Analysis of the adult human plasma metabolome. Pharmacogenomics 9:383\u2013397. https:\/\/doi.org\/10.2217\/14622416.9.4.383","DOI":"10.2217\/14622416.9.4.383"},{"key":"2026070523570932864_j_aite-2025-0011_ref_020","doi-asserted-by":"crossref","unstructured":"Lu Y, Zhang X, Zhao L et al. (2018) Metabolic disturbances in the striatum and substantia Nigra in the onset and progression of MPTP-induced Parkinsonism model. Front Neurosci 12:90. https:\/\/doi.org\/10.3389\/fnins.2018.00090","DOI":"10.3389\/fnins.2018.00090"},{"key":"2026070523570932864_j_aite-2025-0011_ref_021","doi-asserted-by":"crossref","unstructured":"Meoni G, Tenori L, Schade S et al. (2022) Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson\u2019s disease patients. NPJ Parkinsons Dis 8:14. https:\/\/doi.org\/10.1038\/s41531-021-00274-8","DOI":"10.1038\/s41531-021-00274-8"},{"key":"2026070523570932864_j_aite-2025-0011_ref_022","doi-asserted-by":"crossref","unstructured":"Motoi Y, Shimada K, Ishiguro K et al. (2014) Lithium and autophagy. ACS Chem Neurosci 5:434\u2013442. https:\/\/doi.org\/10.1021\/cn500056q","DOI":"10.1021\/cn500056q"},{"key":"2026070523570932864_j_aite-2025-0011_ref_023","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","DOI":"10.1186\/s13643-021-01626-4"},{"key":"2026070523570932864_j_aite-2025-0011_ref_024","doi-asserted-by":"crossref","unstructured":"Peironcely JE, Reijmers T, Coulier L et al. (2011) Understanding and classifying metobolite space and metabolite-likeness. PLoS One 6:e28966. https:\/\/doi.org\/10.1371\/journal.pone.0028966","DOI":"10.1371\/journal.pone.0028966"},{"key":"2026070523570932864_j_aite-2025-0011_ref_025","doi-asserted-by":"crossref","unstructured":"Salek RM, Colebrooke RE, Macintosh R et al. (2008) A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene. Neurochem Res 33:292\u2013300. https:\/\/doi.org\/10.1007\/s11064-007-9542-3","DOI":"10.1007\/s11064-007-9542-3"},{"key":"2026070523570932864_j_aite-2025-0011_ref_026","doi-asserted-by":"crossref","unstructured":"Shen T, Yue Y, He T et al. (2021) The association between the gut microbiota and Parkinson\u2019s disease, a meta-analysis. Front Aging Neurosci 13:636545. https:\/\/doi.org\/10.3389\/fnagi.2021.636545","DOI":"10.3389\/fnagi.2021.636545"},{"key":"2026070523570932864_j_aite-2025-0011_ref_027","doi-asserted-by":"crossref","unstructured":"Solana-Manrique C, Sanz FJ, Torregrosa I et al. (2022) Metabolic alterations in a Drosophila model of Parkinson\u2019s disease based on DJ-1 deficiency. Cells 11:331. https:\/\/doi.org\/10.3390\/cells11030331","DOI":"10.3390\/cells11030331"},{"key":"2026070523570932864_j_aite-2025-0011_ref_028","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al. (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"2026070523570932864_j_aite-2025-0011_ref_029","doi-asserted-by":"crossref","unstructured":"Surguchov A (2022) Biomarkers in Parkinson\u2019s disease. In: Peplow PV, Martinez B, Gennarelli TA (eds) Neurodegenerative diseases biomarkers: towards translating research to clinical practice [Internet]. Springer US, New York, NY, 2022 [cited 2025 Feb 3]. pp. 155\u2013180. https:\/\/doi.org\/10.1007\/978-1-0716-1712-0_7","DOI":"10.1007\/978-1-0716-1712-0_7"},{"key":"2026070523570932864_j_aite-2025-0011_ref_030","doi-asserted-by":"crossref","unstructured":"Toczylowska B, Zieminska E, Micha\u0142owska M et al. (2020) Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients \u2013 in vitro and in vivo NMR spectroscopy studies. Brain Res 1748:147118. https:\/\/doi.org\/10.1016\/j.brainres.2020.147118","DOI":"10.1016\/j.brainres.2020.147118"},{"key":"2026070523570932864_j_aite-2025-0011_ref_031","doi-asserted-by":"crossref","unstructured":"Vilchez D, Saez I, Dillin A (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 5:5659. https:\/\/doi.org\/10.1038\/ncomms6659","DOI":"10.1038\/ncomms6659"},{"key":"2026070523570932864_j_aite-2025-0011_ref_032","doi-asserted-by":"crossref","unstructured":"Villeneuve LM, Purnell PR, Boska MD et al. (2016) Early expression of Parkinson\u2019s disease-related mitochondrial abnormalities in PINK1 knockout rats. Mol Neurobiol 53:171\u2013186. https:\/\/doi.org\/10.1007\/s12035-014-8927-y","DOI":"10.1007\/s12035-014-8927-y"},{"key":"2026070523570932864_j_aite-2025-0011_ref_033","doi-asserted-by":"crossref","unstructured":"Yang W, Hamilton JL, Kopil C et al. (2020b) Current and projected future economic burden of Parkinson\u2019s disease in the U.S. NPJ Parkinsons Dis 6:15. https:\/\/doi.org\/10.1038\/s41531-020-0117-1","DOI":"10.1038\/s41531-020-0117-1"},{"key":"2026070523570932864_j_aite-2025-0011_ref_034","doi-asserted-by":"crossref","unstructured":"Yang C, Zhang T, Wang W et al. (2020a) Brain-region specific metabolic abnormalities in Parkinson\u2019s disease and levodopa-induced dyskinesia. Front Aging Neurosci 12:75. https:\/\/doi.org\/10.3389\/fnagi.2020.00075","DOI":"10.3389\/fnagi.2020.00075"},{"key":"2026070523570932864_j_aite-2025-0011_ref_035","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang S, Fu P et al. (2019) Roles of glutamate receptors in Parkinson\u2019s disease. Int J Mol Sci 20:4391. https:\/\/doi.org\/10.3390\/ijms20184391","DOI":"10.3390\/ijms20184391"},{"key":"2026070523570932864_j_aite-2025-0011_ref_036","doi-asserted-by":"crossref","unstructured":"Zheng H, Zhao L, Xia H et al. (2016) NMR-based metabolomics reveal a recovery from metabolic changes in the striatum of 6-OHDA-induced rats treated with basic fibroblast growth factor. Mol Neurobiol 53:6690\u20136697. https:\/\/doi.org\/10.1007\/s12035-015-9579-2","DOI":"10.1007\/s12035-015-9579-2"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aite-2025-0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T23:57:45Z","timestamp":1783295865000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aite-2025-0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,11]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/aite-2025-0011"],"URL":"https:\/\/doi.org\/10.2478\/aite-2025-0011","relation":{},"ISSN":["1661-4917"],"issn-type":[{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20250011"}}